Modelling the Public Health Impact of MenACWY and MenC Adolescent Vaccination Strategies in Germany
ConclusionThe results of this study demonstrate that implementing MenACWY vaccination for adolescents in Germany is likely to notably reduce IMD incidence and mortality across age groups. However, the introduction of MenC adolescent vaccination shows only limited impact. Considering the extensive healthcare resources typically required for IMD management, these findings suggest the potential for economic benefits associated with the adoption of MenACWY adolescent vaccination, warranting further cost-effectiveness analysis. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - April 4, 2024 Category: Infectious Diseases Source Type: research
Toxic-Induced Encephalopathy Following Chemsex in a Young HIV-Positive Male: A Complex Case of Acute Cognitive Impairment with Anterograde Amnesia and Behavioral Alterations
ConclusionsThe detailed analysis of this case underpins the severe neurological consequences that can manifest from heavy substance use. Comprehensive diagnostic evaluations, including neuroimaging and neuropsychological assessments, are crucial in elucidating the full spectrum of substance-induced cognitive impairments. There is an urgent need for enhanced public awareness and preventative measures, especially in the context of chemsex, to bring forth multifaceted health, social, and government implications that modern society must adeptly navigate. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - April 3, 2024 Category: Infectious Diseases Source Type: research
Real-World Effectiveness of Dolutegravir/Lamivudine in People With HIV-1 in Test-and-Treat Settings or With High Baseline Viral Loads: TANDEM Study Subgroup Analyses
ConclusionsResults demonstrate real-world effectiveness of DTG/3TC, with few discontinuations, in people with HIV-1 in test-and-treat settings or with high baseline viral loads. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - April 3, 2024 Category: Infectious Diseases Source Type: research
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
ConclusionMotivation for selecting DTG-based 2DRs was primarily driven by a desire to avoid or manage toxicities and simplify treatment. Results demonstrate that DTG/3TC and DTG/RPV are effective in real-world settings, with few discontinuations, reflecting data from clinical trials. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - April 3, 2024 Category: Infectious Diseases Source Type: research
Toxic-Induced Encephalopathy Following Chemsex in a Young HIV-Positive Male: A Complex Case of Acute Cognitive Impairment with Anterograde Amnesia and Behavioral Alterations
ConclusionsThe detailed analysis of this case underpins the severe neurological consequences that can manifest from heavy substance use. Comprehensive diagnostic evaluations, including neuroimaging and neuropsychological assessments, are crucial in elucidating the full spectrum of substance-induced cognitive impairments. There is an urgent need for enhanced public awareness and preventative measures, especially in the context of chemsex, to bring forth multifaceted health, social, and government implications that modern society must adeptly navigate. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - April 3, 2024 Category: Infectious Diseases Source Type: research
Real-World Effectiveness of Dolutegravir/Lamivudine in People With HIV-1 in Test-and-Treat Settings or With High Baseline Viral Loads: TANDEM Study Subgroup Analyses
ConclusionsResults demonstrate real-world effectiveness of DTG/3TC, with few discontinuations, in people with HIV-1 in test-and-treat settings or with high baseline viral loads. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - April 3, 2024 Category: Infectious Diseases Source Type: research
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
ConclusionMotivation for selecting DTG-based 2DRs was primarily driven by a desire to avoid or manage toxicities and simplify treatment. Results demonstrate that DTG/3TC and DTG/RPV are effective in real-world settings, with few discontinuations, reflecting data from clinical trials. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - April 3, 2024 Category: Infectious Diseases Source Type: research
Impact of Immunosuppressed Status on Prognosis of Carbapenem-Resistant Organisms Bloodstream Infections
ConclusionDespite the high mortality rate of CRO-BSI, immunosuppression did not affect the mortality. Appropriate antibiotic therapy is crucial for improving the prognosis of CRO-BSI, regardless of the immune status. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - March 27, 2024 Category: Infectious Diseases Source Type: research
Estimated Incidence of Hospitalizations and Deaths Attributable to Respiratory Syncytial Virus Infections Among Adults in Germany Between 2015 and 2019
ConclusionsThis is a first model-based study to comprehensively assess adult RSV burden in Germany. Estimated cardiorespiratory RSV hospitalization rates increased with age and were substantially higher in people with risk factors compared to those without risk factors. Our study indicates that RSV, like other respiratory viruses, contributes to both respiratory and cardiovascular hospitalizations. Effective prevention strategies are needed, especially among older adults ≥ 60 years and among adults with underlying risk factors. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - March 23, 2024 Category: Infectious Diseases Source Type: research
Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States
ConclusionsThese findings highlight the potential of the adjuvanted RSVPreF3 vaccine to substantially reduce RSV disease burden among US older adults aged ≥ 60 years. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - March 20, 2024 Category: Infectious Diseases Source Type: research
